NCT06579209

NAD+ Oral Supplement Pilot Intervention in Adult Females

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: University of Rhode Island · Academic / Other
• Sex: Female
• Age: 40 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are: Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ. Participants will: Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Conditions

• Cognitive Change
• Inflammation
• Neurodegenerative Diseases

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Treatment	Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo.
OTHER	Placebo	Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo pill.

Timeline

• Start date: 2024-12-01
• Primary completion: 2026-02-20
• Completion: 2026-02-20
• First posted: 2024-08-30
• Last updated: 2026-03-12

Locations

2 sites across 1 country: United States